Guidelines for Diagnosis and Management, Fourth Edition

Total Page:16

File Type:pdf, Size:1020Kb

Guidelines for Diagnosis and Management, Fourth Edition Fanconi Anemia: Guidelines for Diagnosis and Management Fourth Edition • 2014 We are deeply grateful to the following generous donors, who made this publication possible: Pat and Stephanie Kilkenny Phil and Penny Knight Disclaimer Information provided in this handbook about medications, treatments or products should not be construed as medical instruction or scientific endorsement. Always consult your physician before taking any action based on this information. copyright© 1999; second edition 2003; third edition 2008; fourth edition 2014 Fanconi Anemia: Guidelines for Diagnosis and Management Fourth Edition • 2014 Managing Editor: Laura Hays, PhD Editors: Dave Frohnmayer, JD, Lynn Frohnmayer, MSW, Eva Guinan, MD, Teresa Kennedy, MA, and Kim Larsen Scientific Writers: SciScripter, LLC These guidelines for the clinical care of Fanconi anemia (FA) were developed at a conference held April 5-6, 2013 in Herndon, VA. We owe a tremendous debt of gratitude to Eva Guinan, MD, for serving as moderator of the conference, as she did for the consensus conferences for the first three editions, and for her skill in helping the participants arrive at consensus. We would like to thank all the participants for donating their time and expertise to develop these guidelines. The names and contact information of all participants appear in the Appendix. These guidelines are posted on our Web site and are available from: Fanconi Anemia Research Fund, Inc. Phone: 541-687-4658 or 888-326-2664 (US only) 1801 Willamette Street, Suite 200 FAX: 541-687-0548 Eugene, Oregon 97401 E-mail: [email protected] Web site: www.fanconi.org Facebook: www.facebook.com/fanconianemiaresearchfund Twitter: https://twitter.com/FAresearchfund Material from this book may be reprinted with the permission of the Fanconi Anemia Research Fund, Inc. The Fanconi Anemia Research Fund, Inc., was founded in 1989 to provide support to FA families and to raise money for scientific research. The Fund publishes a newsletter twice a year, sponsors an annual family meeting and a meeting for adults with FA every 18 months, and provides resource identification and counseling support to families. To aid research into FA, the Fund gives grants to scientists and sponsors scientific conferences, including an annual scientific symposium. Board of Directors Advisor to the Board Barry Rubenstein, JD, President David Frohnmayer, JD Lynn Frohnmayer, MSW, Vice President Scientific Advisory Board Brian Matthews, PhD, Secretary/Treasurer Grover C. Bagby, Jr., MD, Chair Christopher Byrd, Esq. Joseph Califano, MD David Fiaschetti, DDS Richard Gelinas, PhD Amy Frohnmayer, MA Eva Guinan, MD Richard Gelinas, PhD Christopher Mathew, PhD Brian Horrigan Stephen Meyn, MD, PhD Kevin McQueen Raymond J. Monnat, Jr., MD Mark Pearl Elaine Ostrander, PhD Peter Pless, MD Bhuvanesh Singh, MD, PhD Sharon Schuman, PhD Elizabeth Swisher, MD Annette Waxberg, MBA Jakub Tolar, MD, PhD William N. William, Jr., MD Staff Laura Hays, PhD, Executive Director Teresa Kennedy, MA, Director of Family Support Services Cynthia Freeman, Special Projects Coordinator Kristi Keller, Administrative Assistant and Bookkeeper Kim Larsen, Conference Planner and Communications Editor Special thanks to the following authors who made major writing contributions: Blanche P. Alter, MD, MPH, FAAP (Chapter 15) Farid Boulad, MD (Chapter 12) Mercedes Castiel, MD (Chapter 6) Nancy F. Cincotta, MSW, MPhil (Chapter 18) David K. Fiaschetti, DDS (Chapter 10) Lynn Frohnmayer (Chapter 19) Alfred Gillio, MD (Chapter 16) Neelam Giri, MD (Chapter 7) Helmut Hanenberg, MD (Chapters 1 and 3) H. Jeffrey Kim, MD (Chapter 8) Betsy Hirsch, PhD, FACMG (Chapter 2) Sally Kinsey, MD (Chapters 1 and 3) Scott H. Kozin, MD (Chapter 5) David Kutler, MD (Chapter 14) Jeffrey M. Lipton, MD, PhD (Chapters 1 and 3) Jennifer Y. Lin, MD (Chapter 9) Margaret MacMillan, MD (Chapter 20) Susan Olson, PhD, FACMG (Chapter 2) Anna Petryk, MD (Chapter 7) Susan R. Rose, MD (Chapter 7) Philip S. Rosenberg, PhD (Chapter 15) Erica Sanborn, MS (Chapter 17) Mark M. Schubert, DDS, MSD (Chapter 10) Sarah Jane Schwarzenberg, MD (Chapter 4) Roopa Kanakatti Shankar, MD, MS (Chapter 7) Akiko Shimamura, MD, PhD (Chapter 3) Bhuvanesh Singh, MD, PhD (Chapter 14) Pamela Stratton, MD (Chapter 6) Flavia R. Teles, DDS, MS, DMSc (Chapter 10) Jakub Tolar, MD, PhD (Chapter 13) John Wagner, MD (Chapter 11) William William, MD (Chapter 14) Heather Zierhut, PhD, MS, CGC (Chapter 17) Table of Contents Introduction ...........................................................................................................................1 Chapter 1: Diagnosis and Evaluation.........................................................................................6 Chapter 2: Laboratory Diagnostics ..........................................................................................27 Chapter 3: Hematologic Abnormalities in Patients with Fanconi Anemia ....................................43 Chapter 4: Gastrointestinal, Hepatic, and Nutritional Problems ................................................74 Chapter 5: Hand and Arm Abnormalities .................................................................................99 Chapter 6: Issues Facing Women with Fanconi Anemia: Improved Survival and New Dilemmas ...121 Chapter 7: Endocrine Disorders ..........................................................................................142 Chapter 8: Hearing and Ear Abnormalities in Fanconi Anemia .................................................177 Chapter 9: Dermatologic Issues ...........................................................................................194 Chapter 10: Oral and Dental Health Care .............................................................................201 Chapter 11: Hematopoietic Stem Cell Transplantation ...........................................................217 Chapter 12: Long-Term Follow-Up After Transplantation .......................................................242 Chapter 13: Novel Stem Cell Treatment Options ...................................................................257 Chapter 14: Head and Neck Cancers in Patients with Fanconi Anemia ....................................269 Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia ......................285 Chapter 16: The Adult Patient with FA ..................................................................................294 Chapter 17: Genetic Counseling ...........................................................................................306 Chapter 18: Psychosocial Issues .........................................................................................333 Chapter 19: The Grieving Process and the Physician’s Role: A Mother’s Perspective ................352 Chapter 20: Clinical Management Checklist ..........................................................................367 Abbreviations and Important Terms ...................................................................................382 Appendix ............................................................................................................................394 Index ..................................................................................................................................401 Introduction Fanconi Anemia: Guidelines for Diagnosis and Management, Fourth Edition, is the result of a Consensus Conference held by the Fanconi Anemia Research Fund in Herndon, Va., April 5-6, 2013. It replaces earlier editions published in 1999, 2003, and 2008. These guidelines are published for physicians who provide care for FA patients, and for patients and families who wish to secure optimal treatment by improving their understanding of all facets of Fanconi anemia, medical consultation, and appropriate referral. These guidelines begin with detailed information on diagnosis and evaluation of FA. Subsequent chapters examine more specific health issues faced by persons with FA, followed by two chapters on psychosocial considerations that bear upon the well-being of the person with FA and his or her extended family. The guidelines conclude with a comprehensive checklist and diagnostic criteria for physicians and medical specialists. Where possible, the guidelines rely on evidence-based medicine. Where adequate data are lacking because of limitations of numbers, time frame, or present knowl edge, the consensus of expert opinion underlies the rec- ommendations. Every effort has been made to give fair voice to discordant medical opinions when evidence is lacking and controversy exists. All chapters have been peer-reviewed and describe best practices as of the date of publication. To avoid being excessively prescriptive, the title of this book was changed in our last edition from “Standards” to “Guidelines.” From the discussions at this and earlier Consensus Conferences, the authors realize that a more robust clinical database must be developed to gather additional evidence upon which to base recommendations. FA-related science has significantly advanced since the last publication in 2008: • At least 16 FA genes now have been identified. The understanding of interactions among molecular pathways has become increasingly complex and sophisticated. Genotype determination and mutation analysis for each 1 Fanconi Anemia: Guidelines for Diagnosis and Management patient bear directly on the appropriateness of some treatment choices and it is anticipated that this information will become increasing relevant to patient
Recommended publications
  • Glossary for Narrative Writing
    Periodontal Assessment and Treatment Planning Gingival description Color: o pink o erythematous o cyanotic o racial pigmentation o metallic pigmentation o uniformity Contour: o recession o clefts o enlarged papillae o cratered papillae o blunted papillae o highly rolled o bulbous o knife-edged o scalloped o stippled Consistency: o firm o edematous o hyperplastic o fibrotic Band of gingiva: o amount o quality o location o treatability Bleeding tendency: o sulcus base, lining o gingival margins Suppuration Sinus tract formation Pocket depths Pseudopockets Frena Pain Other pathology Dental Description Defective restorations: o overhangs o open contacts o poor contours Fractured cusps 1 ww.links2success.biz [email protected] 914-303-6464 Caries Deposits: o Type . plaque . calculus . stain . matera alba o Location . supragingival . subgingival o Severity . mild . moderate . severe Wear facets Percussion sensitivity Tooth vitality Attrition, erosion, abrasion Occlusal plane level Occlusion findings Furcations Mobility Fremitus Radiographic findings Film dates Crown:root ratio Amount of bone loss o horizontal; vertical o localized; generalized Root length and shape Overhangs Bulbous crowns Fenestrations Dehiscences Tooth resorption Retained root tips Impacted teeth Root proximities Tilted teeth Radiolucencies/opacities Etiologic factors Local: o plaque o calculus o overhangs 2 ww.links2success.biz [email protected] 914-303-6464 o orthodontic apparatus o open margins o open contacts o improper
    [Show full text]
  • Structure and Function of the Human Recq DNA Helicases
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2005 Structure and function of the human RecQ DNA helicases Garcia, P L Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-34420 Dissertation Published Version Originally published at: Garcia, P L. Structure and function of the human RecQ DNA helicases. 2005, University of Zurich, Faculty of Science. Structure and Function of the Human RecQ DNA Helicases Dissertation zur Erlangung der naturwissenschaftlichen Doktorw¨urde (Dr. sc. nat.) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultat¨ der Universitat¨ Z ¨urich von Patrick L. Garcia aus Unterseen BE Promotionskomitee Prof. Dr. Josef Jiricny (Vorsitz) Prof. Dr. Ulrich H ¨ubscher Dr. Pavel Janscak (Leitung der Dissertation) Z ¨urich, 2005 For my parents ii Summary The RecQ DNA helicases are highly conserved from bacteria to man and are required for the maintenance of genomic stability. All unicellular organisms contain a single RecQ helicase, whereas the number of RecQ homologues in higher organisms can vary. Mu- tations in the genes encoding three of the five human members of the RecQ family give rise to autosomal recessive disorders called Bloom syndrome, Werner syndrome and Rothmund-Thomson syndrome. These diseases manifest commonly with genomic in- stability and a high predisposition to cancer. However, the genetic alterations vary as well as the types of tumours in these syndromes. Furthermore, distinct clinical features are observed, like short stature and immunodeficiency in Bloom syndrome patients or premature ageing in Werner Syndrome patients. Also, the biochemical features of the human RecQ-like DNA helicases are diverse, pointing to different roles in the mainte- nance of genomic stability.
    [Show full text]
  • Open Full Page
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Michael F. Walsh1, Vivian Y. Chang2, Wendy K. Kohlmann3, Hamish S. Scott4, Christopher Cunniff5, Franck Bourdeaut6, Jan J. Molenaar7, Christopher C. Porter8, John T. Sandlund9, Sharon E. Plon10, Lisa L. Wang10, and Sharon A. Savage11 Abstract DNA repair syndromes are heterogeneous disorders caused by around the world to discuss and develop cancer surveillance pathogenic variants in genes encoding proteins key in DNA guidelines for children with cancer-prone disorders. Herein, replication and/or the cellular response to DNA damage. The we focus on the more common of the rare DNA repair dis- majority of these syndromes are inherited in an autosomal- orders: ataxia telangiectasia, Bloom syndrome, Fanconi ane- recessive manner, but autosomal-dominant and X-linked reces- mia, dyskeratosis congenita, Nijmegen breakage syndrome, sive disorders also exist. The clinical features of patients with DNA Rothmund–Thomson syndrome, and Xeroderma pigmento- repair syndromes are highly varied and dependent on the under- sum. Dedicated syndrome registries and a combination of lying genetic cause. Notably, all patients have elevated risks of basic science and clinical research have led to important in- syndrome-associated cancers, and many of these cancers present sights into the underlying biology of these disorders. Given the in childhood. Although it is clear that the risk of cancer is rarity of these disorders, it is recommended that centralized increased, there are limited data defining the true incidence of centers of excellence be involved directly or through consulta- cancer and almost no evidence-based approaches to cancer tion in caring for patients with heritable DNA repair syn- surveillance in patients with DNA repair disorders.
    [Show full text]
  • Non-Syndromic Occurrence of True Generalized Microdontia with Mandibular Mesiodens - a Rare Case Seema D Bargale* and Shital DP Kiran
    Bargale and Kiran Head & Face Medicine 2011, 7:19 http://www.head-face-med.com/content/7/1/19 HEAD & FACE MEDICINE CASEREPORT Open Access Non-syndromic occurrence of true generalized microdontia with mandibular mesiodens - a rare case Seema D Bargale* and Shital DP Kiran Abstract Abnormalities in size of teeth and number of teeth are occasionally recorded in clinical cases. True generalized microdontia is rare case in which all the teeth are smaller than normal. Mesiodens is commonly located in maxilary central incisor region and uncommon in the mandible. In the present case a 12 year-old boy was healthy; normal in appearance and the medical history was noncontributory. The patient was examined and found to have permanent teeth that were smaller than those of the average adult teeth. The true generalized microdontia was accompanied by mandibular mesiodens. This is a unique case report of non-syndromic association of mandibular hyperdontia with true generalized microdontia. Keywords: Generalised microdontia, Hyperdontia, Permanent dentition, Mandibular supernumerary tooth Introduction [Ullrich-Turner syndrome], Chromosome 13[trisomy 13], Microdontia is a rare phenomenon. The term microdontia Rothmund-Thomson syndrome, Hallermann-Streiff, Oro- (microdentism, microdontism) is defined as the condition faciodigital syndrome (type 3), Oculo-mandibulo-facial of having abnormally small teeth [1]. According to Boyle, syndrome, Tricho-Rhino-Phalangeal, type1 Branchio- “in general microdontia, the teeth are small, the crowns oculo-facial syndrome. short, and normal contact areas between the teeth are fre- Supernumerary teeth are defined as any supplementary quently missing” [2] Shafer, Hine, and Levy [3] divided tooth or tooth substance in addition to usual configuration microdontia into three types: (1) Microdontia involving of twenty deciduous and thirty two permanent teeth [7].
    [Show full text]
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • Genetic Syndromes and Genes Involved
    ndrom Sy es tic & e G n e e n G e f Connell et al., J Genet Syndr Gene Ther 2013, 4:2 T o Journal of Genetic Syndromes h l e a r n a DOI: 10.4172/2157-7412.1000127 r p u y o J & Gene Therapy ISSN: 2157-7412 Review Article Open Access Genetic Syndromes and Genes Involved in the Development of the Female Reproductive Tract: A Possible Role for Gene Therapy Connell MT1, Owen CM2 and Segars JH3* 1Department of Obstetrics and Gynecology, Truman Medical Center, Kansas City, Missouri 2Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 3Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA Abstract Müllerian and vaginal anomalies are congenital malformations of the female reproductive tract resulting from alterations in the normal developmental pathway of the uterus, cervix, fallopian tubes, and vagina. The most common of the Müllerian anomalies affect the uterus and may adversely impact reproductive outcomes highlighting the importance of gaining understanding of the genetic mechanisms that govern normal and abnormal development of the female reproductive tract. Modern molecular genetics with study of knock out animal models as well as several genetic syndromes featuring abnormalities of the female reproductive tract have identified candidate genes significant to this developmental pathway. Further emphasizing the importance of understanding female reproductive tract development, recent evidence has demonstrated expression of embryologically significant genes in the endometrium of adult mice and humans. This recent work suggests that these genes not only play a role in the proper structural development of the female reproductive tract but also may persist in adults to regulate proper function of the endometrium of the uterus.
    [Show full text]
  • Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in A
    Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in a novel member of the chromodomain gene family cause CHARGE syndrome. L.E.L.M. Vissers1, C.M.A. van Ravenswaaij1, R. Admiraal2, J.A. Hurst3, B.B.A. de Vries1, I.M. Janssen1, W.A. van der Vliet1, E.H.L.P.G. Huys1, P.J. de Jong4, B.C.J. Hamel1, E.F.P.M. Schoenmakers1, H.G. Brunner1, A. Geurts van Kessel1, J.A. Veltman1. 1) Dept Human Genetics, UMC Nijmegen, Nijmegen, Netherlands; 2) Dept Otorhinolaryngology, UMC Nijmegen, Nijmegen, Netherlands; 3) Dept Clinical Genetics, The Churchill Hospital, Oxford, United Kingdom; 4) Children's Hospital Oakland Research Institute, BACPAC Resources, Oakland, CA. CHARGE association denotes the non-random occurrence of ocular coloboma, heart defects, choanal atresia, retarded growth and development, genital hypoplasia, ear anomalies and deafness (OMIM #214800). Almost all patients with CHARGE association are sporadic and its cause was unknown. We and others hypothesized that CHARGE association is due to a genomic microdeletion or to a mutation in a gene affecting early embryonic development. In this study array- based comparative genomic hybridization (array CGH) was used to screen patients with CHARGE association for submicroscopic DNA copy number alterations. De novo overlapping microdeletions in 8q12 were identified in two patients on a genome-wide 1 Mb resolution BAC array. A 2.3 Mb region of deletion overlap was defined using a tiling resolution chromosome 8 microarray. Sequence analysis of genes residing within this critical region revealed mutations in the CHD7 gene in 10 of the 17 CHARGE patients without microdeletions, including 7 heterozygous stop-codon mutations.
    [Show full text]
  • Paroxysmal Nocturnal Haemoglobinuria: a Case Series from Oman Arwa Z
    Paroxysmal Nocturnal Haemoglobinuria: A Case Series from Oman Arwa Z. Al-Riyami1*, Yahya Al-Kindi2, Jamal Al-Qassabi1, Sahimah Al-Mamari1, Naglaa Fawaz1, Murtadha Al-Khabori1 , Mohammed Al-Huneini1 and Salam AlKindi3 1Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman 2College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman 3Department of Hematology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman Received: 17 August 2020 Accepted: 23 December 2020 *Corresponding author: [email protected] DOI 10.5001/omj.2022.13 Abstract Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired stem cell disorder that manifests by hemolytic anemia, thrombosis and cytopenia. There are no data on PNH among Omani patients. Methods We performed a retrospective review of all patients tested for PNH by flow cytometry at the Sultan Qaboos University Hospital between 2012 and 2019. Manifestations, treatment modalities and outcomes were assessed. Results Total of 10 patients were diagnosed or were on follow up for PNH (median age 22.5 years). Clinical manifestations included fatigue (80%) and anemia (70%). There were six patients who had classical PNH with evidence of hemolysis, three patient had PNH in the context of aplastic anemia, and one patient with subclinical PNH. The median reported total type II+III clone size was 95.5 (range 1.54-97) in neutrophils (FLAER/CD24) and 91.6 (range 0.036-99) in monocytes (FLAER/CD14). There were four patients who were found to have a clone size > 50% at time of diagnosis. The median follow up of the patients were 62 months (range: 8-204).
    [Show full text]
  • JACKSON-THESIS-2016.Pdf (1.747Mb)
    Copyright by Kody Sherman Jackson 2016 The Thesis Committee for Kody Sherman Jackson Certifies that this is the approved version of the following thesis: Jesus, Jung, and the Charismatics: The Pecos Benedictines and Visions of Religious Renewal APPROVED BY SUPERVISING COMMITTEE: Supervisor: Robert Abzug Virginia Garrard-Burnett Jesus, Jung, and the Charismatics: The Pecos Benedictines and Visions of Religious Renewal by Kody Sherman Jackson, B.A. Thesis Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Master of Arts The University of Texas at Austin May 2016 Dedication To all those who helped in the publication of this work (especially Bob Abzug and Ginny Burnett), but most especially my brother. Just like my undergraduate thesis, it will be more interesting than anything you ever write. Abstract Jesus, Jung, and the Charismatics: The Pecos Benedictines and Visions of Religious Renewal Kody Sherman Jackson, M.A. The University of Texas at Austin, 2016 Supervisor: Robert Abzug The Catholic Charismatic Renewal, though changing the face and feel of U.S. Catholicism, has received relatively little scholarly attention. Beginning in 1967 and peaking in the mid-1970s, the Renewal brought Pentecostal practices (speaking in tongues, faith healings, prophecy, etc.) into mainstream Catholicism. This thesis seeks to explore the Renewal on the national, regional, and individual level, with particular attention to lay and religious “covenant communities.” These groups of Catholics (and sometimes Protestants) devoted themselves to spreading Pentecostal practices amongst their brethren, sponsoring retreats, authoring pamphlets, and organizing conferences.
    [Show full text]
  • Fanconi Anemia, Bloom Syndrome and Breast Cancer
    A multiprotein complex in DNA damage response network of Fanconi anemia, Bloom syndrome and Breast cancer Weidong Wang Lab of Genetics, NIA A Multi-protein Complex Connects Two Genomic Instability Diseases: Bloom Syndrome and Fanconi Anemia Bloom Syndrome . Genomic Instability: -sister-chromatid exchange . Cancer predisposition . Mutation in BLM, a RecQ DNA Helicase . BLM participates in: HR-dependent DSB repair Recovery of stalled replication forks . BLM works with Topo IIIa and RMI to Suppress crossover recombination Courtesy of Dr. Ian Hickson A Multi-protein Complex Connects Two Genomic Instability Diseases: Bloom Syndrome and Fanconi Anemia P I l o r t n o BLM IP kDa C HeLa BLAP 250 Nuclear Extract 200- BLM* FANCA* 116- TOPO IIIα* 97- BLAP 100 MLH1* BLM IP BLAP 75 * 66- RPA 70 IgG H 45- * 30- RPA32 IgG L 20- * 12- RPA14 Meetei et al. MCB 2003 A Multi-protein Complex Connects Two Genomic Instability Diseases: Bloom Syndrome and Fanconi Anemia P I A C N A F BLM IP HeLa FANCM= FAAP 250 BLAP 250 Nuclear Extract BLM* BLM* * FANCA* FANCA TOPO IIIα* TOPO IIIα* FAAP 100 BLAP 100 FANCB= FAAP 95 MLH1 FANCA IP BLM IP BLAP 75 BLAP 75 RPA70*/FANCG* RPA 70* FANCC*/FANCE* IgG H FANCL= FAAP 43 FANCF* RPA32* IgG L Meetei et al. MCB 2003 Meetei et al. Nat Genet. 2003, 2004, 2005 BRAFT-a Multisubunit Machine that Maintains Genome Stability and is defective in Fanconi anemia and Bloom syndrome BRAFT Super-complex Fanconi Anemia Bloom Syndrome Core Complex Complex 12 polypeptides 7 polypeptides FANCA BLM Helicase (HJ, fork, D-loop), fork FANCC regression, dHJ dissolution Topo IIIα Topoisomerase, FANCE dHJ dissolution FANCF BLAP75 RMI1 FANCG Stimulates dHJ dissolution.
    [Show full text]
  • Beckwith's Syndrome) M
    Postgrad Med J: first published as 10.1136/pgmj.46.533.162 on 1 March 1970. Downloaded from 162 Case reports VAN DER SLUYS VEER, J., CHOUFOER, J.C., QUERIDO, A., Lancet, i, 1416. VAN DER HEUL, R.O., HOLLANDER, C.F. & VAN RIJSSEL, ZOLLINGER, R.M. & ELLIOTT, D.W. (1959) Pancreatic T.G. (1964) Metastasizing islet cell tumour of the pancreas endocrine function and peptic ulceration. Gastroenter- associated with hypoglycaemia and carcinoid syndrome. ology, 37, 401. Macroglossia, abnormal umbilicus and hypoglycaemia (Beckwith's syndrome) M. W. MONCRIEFF* J. R. MANN M.A., B.M., M.R.C.P. M.B., M.R.C.P., D.C.H. Lecturer in Paediatrics, Registrar in Paediatrics, University of Birmingham Birmingham Children's Hospital A. R. GOLDSMITH G. W. CHANCE M.B.B.S. M.B., M.R.C.P., D.C.H. Registrar in Pathology, Senior Lecturer in Paediatrics, Birmingham Children's Hospital University ofBirmingham Introduction lobe and three had a dome-like elevation of the The syndrome of exomphalos, macroglossia, post- posterior part of the diaphragm. The six surviving natal somatic gigantism and severe hypoglycaemia children developed a characteristic facies with prog- copyright. in various combinations was first described in seven nathos, mid-facial under development and slight infants by Beckwith (1963) and Beckwith et al. exophthalmos, and a mid-line frontal ridge. Post- (1964). At necropsy the main features were cyto- natal somatic gigantism occurred in five of the six megaly of the foetal adrenal cortex, renal medullary survivors. A further seven cases with macroglossia dysplasia, and hyperplasia of the pancreas and and umbilical abnormality were reported by Shafer kidneys.
    [Show full text]
  • Blueprint of Pediatric Endocrinology Book
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/317428263 blueprint of pediatric endocrinology book Book · January 2014 CITATIONS READS 0 27 1 author: Abdulmoein Eid Al - Agha King Abdulaziz University 148 PUBLICATIONS 123 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: HYPOPHOSPHATEMIC RICKETS, EPIDERMAL NEVUS SYNDROME WITH... View project HYPERTRIGLYCERIDAEMIA-INDUCED ACUTE PANCREATITIS IN AN INFANT: A CASE REPORT View project All content following this page was uploaded by Abdulmoein Eid Al - Agha on 09 June 2017. The user has requested enhancement of the downloaded file. IN THE NAME OF ALLAH, THE MERCIFUL, THE MERCY-GIVING iii Blueprint in Pediatric Endocrinology Abdulmoein Eid Al-Agha, MBBS, DCH, FRCPCH Pediatric Endocrinologist King AbdulAziz University Faculty of Medicine Jeddah, Saudi Arabia © King Abdulaziz University: 1435 A.H. (2014 AD.) All rights reserved. 1st Edition: 1435 A.H. (2014 A.D.) Table of Contents Chapter 1: Basic Endocrinology Introduction…………………………………………………………………….. 3 Effects of hormones…………………………………………………………….. 3 Types of hormones……………………………………………………………… 4 Types of Hormone Receptors………………...………………………………... 5 Loss – of – function mutations………………………………………………….. 7 Gain – of – function mutations……………………………...………………….. 9 Fetal Brain Programming ………………………………………………………. 10 The endocrine system ……………………………...…………………………... 10 Hypothalamic-Pituitary Relationships………………………………………….. 10 Hypothalamic Controls………………………………………………………….
    [Show full text]